Sublingual immunotherapy and allergic rhinitis
This paper reviews the safety and efficacy of sublingual immunotherapy (SLIT) in the treatment of allergic rhinitis. The literature from 1986 through 2007 shows approximately a 6000-fold range in doses found to be effective with SLIT. However, recent studies in large patient populations have demonstrated a clear dose response with an effective dose range that appears to be equivalent to one to two times the monthly subcutaneous immunotherapy dose administered daily or weekly (ie, 15 to 30 μg of major allergen). Further study is needed to establish the optimal dose and dosing schedule for each formulation. Local reactions (eg, oral itchiness) are common, and serious adverse reactions, although rare, have been reported. Cost-effective analysis cannot be made until the effective dose is established. SLIT appears to be a promising treatment for allergic rhinitis, but it is currently considered investigational in the United States until a formulation approved by the US Food and Drug Administration is available.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 10.Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group [no authors listed]. N Engl J Med 2000, 343:1054–1063.Google Scholar
- 12.Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology: Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007, 120:S25–S85.CrossRefGoogle Scholar
- 14.Alvarez-Cuesta E, Berges-Gimeno P, Gonzalez-Mancebo E, et al.: Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study. Allergy 2007, 62:810–817. [Published erratum appears in Allergy 2007, 62:1100.]PubMedCrossRefGoogle Scholar
- 21.Dahl R, Kapp A, Colombo G, et al.: Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2007, Epub ahead of print.Google Scholar
- 28.Wilson DR, Torres LI, Durham SR: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003, 2:CD002893.Google Scholar
- 29.Calderon MA, Alves B, Jacobson M, et al.: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, 1:CD001936.Google Scholar
- 36.Tari MG, Mancino M, Monti G: Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990, 18:277–284.Google Scholar
- 37.Rolinck-Werninghaus C, Wolf H, Liebke C, et al.: A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004, 59:1285–1293.PubMedCrossRefGoogle Scholar
- 48.Andre C, Perrin-Fayolle M, Grosclaude M, et al.: A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003, 131:111–118.PubMedCrossRefGoogle Scholar